Insider Buying: Medifast (NYSE:MED) Director Acquires 29,337 Shares of Stock

Key Points

• Medifast Director Parsa Kiai bought 29,337 shares at an average price of $11.66, investing about $342,069 and increasing his direct stake by 4.97% to 619,331 shares. He also purchased an additional 43,150 shares the following day for approximately $500,540.
• Medifast’s shares recently traded at $11.87, while the company reported quarterly revenue of $76.38 million and an adjusted loss of $0.28 per share—better than analysts’ expectations but still reflecting negative profitability.
• Analyst sentiment remains cautious: the stock has a consensus rating of “Reduce” and a $12.00 price target. Institutional investors and hedge funds own approximately 95.51% of Medifast’s outstanding shares.

Medifast Inc (NYSE:MED - Get Free Report) Director Parsa Kiai acquired 29,337 shares of the business's stock in a transaction that occurred on Wednesday, August 19th. The stock was bought at an average cost of $11.66 per share, for a total transaction of $342,069.42. Following the completion of the transaction, the director directly owned 619,331 shares in the company, valued at $7,221,399.46. This represents a 4.97% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai bought 43,150 shares of Medifast stock. The stock was bought at an average cost of $11.60 per share, with a total value of $500,540.00.

Medifast Price Performance

MED stock traded up $0.25 during trading hours on Friday, reaching $11.87. 54,923 shares of the stock were exchanged, compared to its average volume of 231,125. The firm's 50-day moving average is $10.92 and its 200-day moving average is $11.06. Medifast Inc has a 12 month low of $9.22 and a 12 month high of $14.67. The company has a market cap of $132.71 million, a price-to-earnings ratio of -5.09 and a beta of 0.65.

Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.37. The company had revenue of $76.38 million for the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative return on equity of 6.69% and a negative net margin of 8.08%.Medifast has set its FY 2026 guidance at -1.750--0.250 EPS and its Q3 2026 guidance at -0.650--0.150 EPS. As a group, equities research analysts forecast that Medifast Inc will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Medifast

Several institutional investors and hedge funds have recently modified their holdings of the stock. PDT Partners LLC bought a new stake in shares of Medifast during the 2nd quarter worth about $348,000. Ieq Capital LLC acquired a new stake in Medifast during the second quarter worth approximately $114,000. Great Lakes Advisors LLC acquired a new stake in Medifast during the second quarter worth approximately $548,000. State of Wyoming bought a new stake in shares of Medifast during the second quarter worth approximately $197,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Medifast during the second quarter worth approximately $408,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MED has been the topic of several research reports. Zacks Research cut Medifast from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Medifast from a "sell (e+)" rating to a "sell (d)" rating in a research note on Monday. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and a consensus price target of $12.00.

About Medifast

Medifast, Inc NYSE: MED is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source